Tor-Einar Svae, Head of IBU Immunotherapy Octapharma Group

Our specialization in immunotherapy warrants the continuous improvement and development of therapeutic concepts in numerous medical areas. It is this long-term commitment of Octapharma to patients requiring immunoglobulin which makes a difference.

High purity 5% IVIG with long-term documented efficacy and tolerability

 

High purity 10% IVIG with proven safety and tolerability at high infusion rates

 

High purity,  high concentration 16.5% SCIG with low viscosity and long-term documented tolerability 

Immunoglobulin containing Rh(D) antibodies obtained from immunized donors which prevents hemolytic disease of the newborn

 

banner_iphone_app octagam_seite appstore_apple appstore_ipad Android Seite

Healthcare Professionals : Immunotherapy

Immunotherapy is not merely a drug or class of drugs, but rather a therapeutic principal that aims to treat immune-mediated diseases and deficiencies by inducing, enhancing, or suppressing an immune response through immunomodulation or immunoglobulin replacement therapy.

Octapharma’s high-purity human immunoglobulin products are amongst the most tolerable of their class and market leaders in many countries. These products form the lifeline to health and hope for countless patients and their families around the globe.

Why do we make a difference in immunotherapy?

Our ability and willingness to go from good to great, our long term commitment to patients requiring immunoglobulin make a difference as shown in our unique immunoglobulin portfolio offering different concentrations (5%, 10%, 16%) and routes of administration (subcutaneous and intravenous) as liquid ready-to-use solutions. Our competence and specialization in immunotherapy warrant therapies for now and in the future which users entrust with their lives for many years.

This unique portfolio offers multiple advantages:

  • A common production process facilitating the switch between Octapharma immunoglobulin products for the patients without triggering tolerability issues
  • Different product concentrations and routes of administration

  • Broad range of filling sizes

  • Simplified supply management of products coming from one single partner

  • A trusted company exclusively dedicated to human plasma and protein therapies

Our Commitment to Immunotherapy

Octapharma continuously seeks to improve immunotherapy products and find new applications. Our unique focus on discovering, developing and producing plasma-derived biopharmaceuticals has resulted in an accumulation of in-depth knowledge on these products and their manufacture.